Gufic Biosciences Pays ₹1.72 Lakh Penalty to BSE for Director Appointment Non-Compliance
Gufic Biosciences paid a penalty of ₹1,72,000 to BSE on March 13, 2026. This is for alleged non-compliance regarding the appointment of an independent director over 75 years old without shareholder approval. The company had previously paid ₹8,000 to BSE and NSE for similar non-compliance in Q2 FY25.
The penalty amount of ₹1,72,000 is relatively small for a listed company and is unlikely to have a significant financial impact. The issue pertains to a specific regulatory compliance which has been addressed by payment.
The company has incurred penalties due to non-compliance with SEBI regulations regarding director appointments, which is a negative development.
Gufic Biosciences Limited has paid a penalty of ₹1,72,000 (excluding GST) to BSE on March 13, 2026. This payment is in relation to the alleged non-compliance with Regulation 17(1A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The non-compliance pertains to the appointment of Mr. Kamal Kishore Seth as an Additional Director (Non-Executive Independent Director) who had attained the age of seventy-five years without obtaining shareholders' approval via a special resolution.
Previously, the company had paid a penalty of ₹8,000 (excluding GST) to both BSE and NSE for the quarter ended June 30, 2024. The company had filed a waiver application for these penalties. However, BSE has communicated the rejection of the waiver application for the September 30, 2024 quarter, leading to the payment of the ₹1,72,000 penalty.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.